JNJ 56136379

Drug Profile

JNJ 56136379

Alternative Names: JNJ-379; JNJ-56136379

Latest Information Update: 18 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Class Antivirals
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 27 Mar 2017 Janssen initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT03111511)
  • 04 Feb 2017 Janssen Research & Development completes a phase I trial in Healthy volunteers in USA (PO, Tablet) (NCT02933580)
  • 11 Nov 2016 Interim adverse events and pharmacokinetics data of a phase I trial in Hepatitis B presented at The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top